# Celldex Shares Slip 2% After Barzolvolimab Misses Goals in Atopic Dermatitis Trial

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/61713
Published: 2026-11-19T22:17:54.000Z
Updated: 2026-11-19T22:17:54.000Z
Section: Business

> A phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints. Celldex shares fell about 2% in after-hours trading Thursday, Nov. 19.

Celldex Therapeutics, Inc. (CLDX) shares fell about 2% in after-hours trading Thursday, Nov. 19, after a phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints.

The trial measured the percent change in weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) score.

The decline in after-hours trading was modest, at about 2%.


